Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    Ethyl pyruvate

    go.drugbank.com/drugs/DB05869
    Investigational

    CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.

  2. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

  3. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

  4. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

  5. Drug

    Sulfameter

    go.drugbank.com/drugs/DB06821
    Approved

    Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.

  6. Drug

    Mucor circinelloides f. lusitanicus

    go.drugbank.com/drugs/DB15525
    Approved

    Mucor circinelloides f. lusitanicus allergenic extract is used in allergenic testing.

  7. Drug

    Coffea arabica seed, roasted

    go.drugbank.com/drugs/DB15603
    Approved

    Coffea arabica seed, roasted allergenic extract is used in allergenic testing.

  8. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  9. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.

  10. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.